BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 33432021)

  • 21. Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making.
    Jorge S; McFaddin AS; Doll KM; Pennington KP; Norquist BM; Bennett RL; Pritchard CC; Swisher EM
    Gynecol Oncol; 2020 Mar; 156(3):517-522. PubMed ID: 31883735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations.
    Ogasawara A; Hihara T; Shintani D; Yabuno A; Ikeda Y; Tai K; Fujiwara K; Watanabe K; Hasegawa K
    Cancer Res Treat; 2020 Oct; 52(4):1219-1228. PubMed ID: 32599986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
    Gadducci A; Guarneri V; Peccatori FA; Ronzino G; Scandurra G; Zamagni C; Zola P; Salutari V
    J Ovarian Res; 2019 Jan; 12(1):9. PubMed ID: 30691488
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutational Aberrations Detected in Mucinous Epithelial Ovarian Cancer of Asian Women.
    Chay WY; Kwok LL; Tiong WN; Krisna SS; Lim KH; Iyer NG; Goh LK; Tan DS
    Int J Gynecol Cancer; 2018 Mar; 28(3):428-436. PubMed ID: 29465505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and Genetic Characteristics of BRCA1/2 Mutation in Korean Ovarian Cancer Patients: A Multicenter Study and Literature Review.
    Kwon BS; Byun JM; Lee HJ; Jeong DH; Lee TH; Shin KH; Suh DS; Kim KH
    Cancer Res Treat; 2019 Jul; 51(3):941-950. PubMed ID: 30309222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer.
    Nodin B; Zendehrokh N; Sundström M; Jirström K
    Diagn Pathol; 2013 Jun; 8():106. PubMed ID: 23800114
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RNF43 mutations are recurrent in Chinese patients with mucinous ovarian carcinoma but absent in other subtypes of ovarian cancer.
    Zou Y; Wang F; Liu FY; Huang MZ; Li W; Yuan XQ; Huang OP; He M
    Gene; 2013 Nov; 531(1):112-6. PubMed ID: 24001777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian carcinoma.
    Krimmel-Morrison JD; Ghezelayagh TS; Lian S; Zhang Y; Fredrickson J; Nachmanson D; Baker KT; Radke MR; Hun E; Norquist BM; Emond MJ; Swisher EM; Risques RA
    Gynecol Oncol; 2020 Feb; 156(2):407-414. PubMed ID: 31839337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Somatic genomic landscape of East Asian epithelial ovarian carcinoma and its clinical implications from prospective clinical sequencing: A Korean Gynecologic Oncology Group study (KGOG 3047).
    Sa JK; Kim J; Kang S; Kim SW; Song T; Shim SH; Choi MC; No JH; Song JY; Kim D; Kim YM; Kim JH; Lee JW
    Int J Cancer; 2022 Oct; 151(7):1086-1097. PubMed ID: 35666535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer.
    Paik ES; Heo EJ; Choi CH; Kim JH; Kim JW; Kim YM; Park SY; Lee JW; Kim JW; Kim BG
    Cancer Sci; 2021 Dec; 112(12):5055-5067. PubMed ID: 34657357
    [TBL] [Abstract][Full Text] [Related]  

  • 31. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients.
    Ye JX; Liu Y; Qin Y; Zhong HH; Yi WN; Shi XY
    World J Gastroenterol; 2015 Feb; 21(5):1595-605. PubMed ID: 25663779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functional polymorphisms in FOXC2 gene and Epithelial ovarian Cancer susceptibility in Chinese population.
    Zhou Z; Ou X; Zou Q; Chu L; Quan X; Chen Y; Liu Y
    J Ovarian Res; 2020 Mar; 13(1):34. PubMed ID: 32222147
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes.
    da Costa AABA; do Canto LM; Larsen SJ; Ribeiro ARG; Stecca CE; Petersen AH; Aagaard MM; de Brot L; Baumbach J; Baiocchi G; Achatz MI; Rogatto SR
    BMC Cancer; 2019 May; 19(1):422. PubMed ID: 31060523
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification and clinical significance of somatic oncogenic mutations in epithelial ovarian cancer.
    Watanabe T; Nanamiya H; Endo Y; Kojima M; Nomura S; Furukawa S; Soeda S; Tamura H; Ryufuku M; Tanaka D; Isogai T; Imai JI; Watanabe S; Fujimori K
    J Ovarian Res; 2021 Oct; 14(1):129. PubMed ID: 34615547
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
    Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
    JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Screening for
    Al-Qahtani WS; Alduwish MA; Al-Olayan EM; Aljarba NH; Em AH; Albani FG; Domiaty DM; Al-Otaibi AM; Qattan SMA; Almurshedi AS; Elasbali AM; Ahmed HG; Almutlaq BA
    J Obstet Gynaecol; 2021 Oct; 41(7):1127-1133. PubMed ID: 33475035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer.
    Chao A; Chang TC; Lapke N; Jung SM; Chi P; Chen CH; Yang LY; Lin CT; Huang HJ; Chou HH; Liou JD; Chen SJ; Wang TH; Lai CH
    Oncotarget; 2016 Dec; 7(51):85529-85541. PubMed ID: 27907908
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
    Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
    Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach.
    Garziera M; Roncato R; Montico M; De Mattia E; Gagno S; Poletto E; Scalone S; Canzonieri V; Giorda G; Sorio R; Cecchin E; Toffoli G
    Cells; 2019 Jun; 8(6):. PubMed ID: 31197119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls.
    Li A; Xie R; Zhi Q; Deng Y; Wu Y; Li W; Yang L; Jiao Z; Luo J; Zi Y; Sun G; Zhang J; Shi Y; Liu J
    Gynecol Oncol; 2018 Oct; 151(1):145-152. PubMed ID: 30078507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.